Log In
BCIQ
Print this Print this
 

ABTL0812

  Manage Alerts
Collapse Summary General Information
Company Ability Pharmaceuticals S.L.
DescriptionSmall molecule inhibitor of mammalian target of rapamycin (mTOR; FRAP; RAFT1) and protein kinase B (AKT; AKT1; PKB; PKBA)
Molecular Target Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) ; Protein kinase B (AKT) (AKT1) (PKB) (PKBA)
Mechanism of ActionMammalian target of rapamycin (mTOR) kinase inhibitor; Protein kinase B (PKB) (AKT1) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$20.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/11/2016

$20.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today